Journal
FREE RADICAL BIOLOGY AND MEDICINE
Volume 171, Issue -, Pages 156-168Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.freeradbiomed.2021.05.008
Keywords
Astaxanthin; Meta-analysis; Metabolic syndrome; Non-alcoholic fatty liver disease; Obesity; Type 2 diabetes
Funding
- University of Basilicata
Ask authors/readers for more resources
This study systematically reviewed the effects of astaxanthin (ASX) in animal models of diet-induced obesity-associated diseases. The results showed that ASX can reduce adipose tissue weight, lower blood pressure, decrease serum glucose levels, improve disease biomarkers in the blood, and reduce liver and body weight in animal models of non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D).
Background and aim: Obesity is a major risk factor for several diseases, including metabolic syndrome (MetS), non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes (T2D). The use of natural products, such as astaxanthin (ASX), a potent antioxidant compound produced by the freshwater green microalga Haematococcus pluvialis, has gained particular interest to reduce oxidative stress and inflammation, and to improve redox status, often associated with obesity. A systematic review and meta-analysis was performed to comprehensively examine the effects of ASX in animal models of diet induced obesity-associated diseases in order to inform the design of future human clinical studies for ASX use as supplement or nutraceutical. Methods: Cinahl, Cochraine, MEDLINE, Scopus and Web of Science were searched for English-language manuscripts published between January 2000 and April 2020 using the following key words: astaxanthin, obesity, non-alcoholic fatty liver disease, diabetes mellitus type 2, NAFLD and metabolic. Results: Seventeen eligible articles, corresponding to 21 animal studies, were included in the final quantitative analysis. ASX, at different concentrations and administered for different length of time, induced a significant reduction in adipose tissue weight (P = 0.05) and systolic blood pressure (P < 0.0001) in control animals. In animal models of T2D, ASX significantly reduced serum glucose levels (P = 0.04); whereas it improved several disease biomarkers in the blood (e.g. cholesterol, triglycerides, ALT and AST, P < 0.10), and reduced liver (P = 0.0002) and body weight (P = 0.11), in animal models of NAFLD. Conclusions: Supplementation of ASX in the diet has positive effects on symptoms associated with obesity related diseases in animals, by having lipid-lowering, hypo-insulin and hypoglycaemic capacity, protecting organs from oxidative stress and mitigating the immune system, as suggested in this review.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available